{"id":"epoetin-alfa-3-times-weekly-once-weekly","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Thrombotic events (stroke, myocardial infarction, deep vein thrombosis)"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201565","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin alfa is a glycoprotein that mimics endogenous erythropoietin, promoting the proliferation and differentiation of erythroid progenitor cells in the bone marrow. This leads to increased reticulocyte production and elevated hemoglobin levels. The drug is used to treat anemia associated with chronic kidney disease, cancer chemotherapy, and other conditions causing reduced red blood cell production.","oneSentence":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:18.800Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in cancer patients receiving chemotherapy"},{"name":"Anemia in patients with HIV infection on antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT04313153","phase":"PHASE3","title":"Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2020-05-27","conditions":"Anemia","enrollment":319},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":"Anemia, End Stage Renal Disease (ESRD)","enrollment":838},{"nctId":"NCT05810311","phase":"PHASE2","title":"The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06-01","conditions":"Diabetes Complications, Diabetes; Nephropathy (Manifestation)","enrollment":30},{"nctId":"NCT05265325","phase":"PHASE2","title":"A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2023-05-03","conditions":"Renal Anemia","enrollment":175},{"nctId":"NCT05699109","phase":"","title":"Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-01-01","conditions":"Anemia of Chronic Kidney Disease, Chronic Renal Failure, Chronic Renal Failure Anemia","enrollment":127},{"nctId":"NCT03799627","phase":"PHASE2","title":"Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2019-01-31","conditions":"Anemia, Dialysis-dependent Chronic Kidney Disease","enrollment":175},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT01235923","phase":"PHASE2","title":"Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2006-04","conditions":"Preterm Infants","enrollment":20},{"nctId":"NCT01023035","phase":"PHASE3","title":"Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-07","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT01975818","phase":"PHASE2","title":"Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-10-28","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":201},{"nctId":"NCT00334737","phase":"PHASE2","title":"Darbepoetin Administration to Preterm Infants","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2006-06","conditions":"Infant, Newborn","enrollment":102},{"nctId":"NCT00711958","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-11","conditions":"Anemia","enrollment":114},{"nctId":"NCT00077610","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Anemia","enrollment":673},{"nctId":"NCT00077623","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Anemia","enrollment":572},{"nctId":"NCT02586402","phase":"PHASE2","title":"Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2015-10","conditions":"Chronic Renal Failure, Anemia, Dialysis","enrollment":60},{"nctId":"NCT01111630","phase":"PHASE4","title":"Study of Erythropoietin (EPO) Administration Schedule","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Chronic Renal Failure, Anaemia","enrollment":60},{"nctId":"NCT00440557","phase":"PHASE3","title":"An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-09","conditions":"Anemia","enrollment":375},{"nctId":"NCT00597584","phase":"PHASE3","title":"Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Affymax","startDate":"2007-10","conditions":"Chronic Renal Failure, Chronic Kidney Disease, Anemia","enrollment":823}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PROCRIT"],"phase":"phase_3","status":"active","brandName":"Epoetin alfa 3 times weekly /once weekly","genericName":"Epoetin alfa 3 times weekly /once weekly","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in cancer patients receiving chemotherapy, Anemia in patients with HIV infection on antiretroviral therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}